NEWARK — CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company, has received a $1 million investment from the State of Delaware to support its lead program targeting next-generation treatments for solid tumors, including head and neck and lung cancers. “We’re excited to have the State of Delaware participate in our Series A financing round as we advance toward our first-in-human clinical …
Click on the image below to view as a PDF This Week’s Top Headlines Include: Headlines Delaware still expects $963.5 surplus for 2024 budget School board elections: turnout low, but rising in places Revamped summer school lets students get ahead, stay active Culture Clifford Brown Jazz Fest releases lineup Darley House envisioned as home for Claymont entrepreneurs New York man …
CorriXR Therapeutics was given the “Most Promising New Company” award by attendees at the inaugural Delaware’s DNA 2023 Life Science Conference. Sponsored by Delaware Bio, the conference attracted 300 people to network and hear panels about industry trends. CorriXR, the first spin-out of ChristianaCare’s Gene Editing Institute, is an oncology-focused biotherapeutics development company with what they describe as a ground-breaking …
